La regresión de la hipertrofia cardíaca inducida por inhibición del NHE-1 se acompaña de disminución de la expresión de calcineurina A.

GARCIARENA CD; ENNIS IL; ESCUDERO EM; CINGOLANI HE

Mar del Plata, Buenos Aires

Congreso; 50 Reunión Científica Anual de la Sociedad Argentina de Investigación Clínica; 2005

SHR with cardiac hypertrophy (CH) were treated with the NHE-1 inhibitors cariporide or BIIB723. NHE-1 blockade induced CH regression evidenced by a decrease in left ventricular (LV) weight/body weigh (LVW/BW) and myocardial BNP and calcineurin (Cn) Ab expression, without changing blood pressure. The reduction in LV mass without changes LV pressure significantly increased peak-systolic stress in treated SHR. Despite this, fractional shortening did not decrease and even an increase in mid-wall shortening was detected, suggesting that a positive inotropic effect develops after CH regression. This was not due to an intrinsic effect of the NHE-1 inhibitors. NHE-1 inhibition-induced CH regression was accompanied by decreased CnAb expression and maintained cardiac function despite the increase in LV wall tension, suggesting a cause-and-effect relationship between Cn expression and contractility. SHR SHR-cariporide SHR-BIIB723 LVW/BW (mg/g) 2.97±0.06 2.58±0.0 2.45±0.12 BNP (% vs. SHR) 100±7 57±17 26±4 CnAb (arbitrary units) 23.75±2.11 6.36±0.58 9.45±1.26